Program
retatrutide
Also written as “Retatrutide”, “LY3437943” and “Retatrutide (LY3437943)”.
Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Atherosclerosis · Non-alcoholic Fatty Liver Disease · Diabetes Mellitus, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 3210 open or running | phase 3since May 22, 2023 | Feb 13, 2019 | Nov 2026phase 3 · NCT06662383 |
| Hudson Biotech | 11 open or running | phase 2since Mar 8, 2026 | Mar 8, 2026 | Mar 14, 2027phase 2 · NCT07467447 |
- Named in Eli Lilly’s own pipeline as
Retatrutide
, phase 3, as of Oct 29, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 17 studies since Feb 13, 2019.
- Sep 11, 2023Phase 1 study in OverweightEli Lilly · NCT06039826 · 46 enrolled · United States
- Feb 8, 2024Phase 3 study in Diabetes Mellitus, Type 2Eli Lilly · NCT06260722 · 1,250 enrolled · United States, Argentina, Canada and more
- Mar 1, 2024Phase 3 study in Diabetes Mellitus, Type 2Eli Lilly · NCT06297603 · 320 enrolled · United States, Argentina, Brazil and more
- Mar 11, 2024Phase 1 study in ObesityEli Lilly · NCT06313528 · 85 enrolled · United States
- Apr 3, 20242 phase 3 studiesEli Lilly · NCT06354660, NCT06383390
- Oct 25, 2024Phase 3 study in ObesityEli Lilly · NCT06662383 · 800 enrolled · United States, Argentina, Germany and more
- Jan 31, 2025Phase 1 study in HealthyEli Lilly · NCT06808802 · 30 enrolled · Singapore
- Feb 28, 2025Phase 3 study in ObesityEli Lilly · NCT06859268 · 643 enrolled · United States, Canada, United Kingdom
- May 14, 20252 phase 1 studiesEli Lilly · NCT06982859, NCT06982846
- May 28, 2025Phase 3 study in ObesityEli Lilly · NCT07035093 · 586 enrolled · United States, Argentina, Canada and more
- Aug 28, 2025Phase 3 study in Non-alcoholic Fatty Liver DiseaseEli Lilly · NCT07165028 · 4,500 planned · United States, Argentina, Australia and more
- Nov 14, 2025Phase 3 study in ObesityEli Lilly · NCT07232719 · 250 enrolled · United States, United Kingdom
- Jan 16, 2026Phase 3 study in ObesityEli Lilly · NCT07357415 · 600 enrolled · United States, Argentina, Canada
- Mar 8, 2026Hudson Biotech's first study: phase 2 study in ObesityNew to Hudson BiotechHudson Biotech · NCT07467447 · 300 planned · China
Ahead
- Nov 2026Primary completion: phase 3 study in ObesityEli Lilly · NCT06662383
- Jan 2027Primary completion: phase 1 study in Diabetes MellitusEli Lilly · NCT06982859
- Mar 14, 2027Primary completion: phase 2 study in ObesityHudson Biotech · NCT07467447
- Jun 2027Primary completion: phase 3 study in ObesityEli Lilly · NCT07232719
TargetBeta
“Glucagon receptor agonist; Glucagon-like peptide 1 receptor agonist; Gastric inhibitory polypeptide receptor agonist”ChEMBL 37, by rule
Other programs on the same three targets
Studies
All 33 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07467447Obesity · China | 2 | Recruiting | Hudson Biotech | Mar 14, 2027 | 300 |
| NCT07357415Obesity · United States, Argentina, Canada | 3 | Active, not recruiting | Eli Lilly | Oct 2028 | 600 |
| NCT07232719Obesity · United States, United Kingdom | 3 | Active, not recruiting | Eli Lilly | Jun 2027 | 250 |
| NCT07165028Non-alcoholic Fatty Liver Disease · United States, Argentina, Australia and more | 3 | Recruiting | Eli Lilly | Aug 2030 | 4,500 |
| NCT07035093Obesity · United States, Argentina, Canada and more | 3 | Active, not recruiting | Eli Lilly | Sep 2027 | 586 |
| NCT06982859Diabetes Mellitus · Germany | 1 | Active, not recruiting | Eli Lilly | Jan 2027 | 95 |
| NCT06982846Diabetes Mellitus, Type 2 · Austria | 1 | Completed | Eli Lilly | May 4, 2026 | 80 |
| NCT06859268Obesity · United States, Canada, United Kingdom | 3 | Active, not recruiting | Eli Lilly | Apr 2028 | 643 |
| NCT06808802Healthy · Singapore | 1 | Completed | Eli Lilly | Apr 15, 2025 | 30 |
| NCT06662383Obesity · United States, Argentina, Germany and more | 3 | Active, not recruiting | Eli Lilly | Nov 2026 | 800 |
| NCT06383390Atherosclerosis · United States, Argentina, Australia and more | 3 | Active, not recruiting | Eli Lilly | Feb 2029 | 10,000 |
| NCT06354660Diabetes Mellitus, Type 2 · United States, India, Mexico and more | 3 | Completed | Eli Lilly | Jan 22, 2026 | 537 |
| NCT06313528Obesity · United States | 1 | Completed | Eli Lilly | Aug 26, 2025 | 85 |
| NCT06297603Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more | 3 | Active, not recruiting | Eli Lilly | Oct 26, 2026 | 320 |
| NCT06260722Diabetes Mellitus, Type 2 · United States, Argentina, Canada and more | 3 | Active, not recruiting | Eli Lilly | Aug 27, 2026 | 1,250 |
| NCT06039826Overweight · United States | 1 | Completed | Eli Lilly | Jul 11, 2024 | 46 |
| NCT06003465Healthy · United States | 1 | Completed | Eli Lilly | Feb 8, 2024 | 57 |
| NCT05959096Healthy · United States | 1 | Completed | Eli Lilly | Jul 25, 2024 | 85 |
| NCT05936151Overweight · United States, Canada, Italy and more | 2 | Completed | Eli Lilly | Oct 1, 2025 | 146 |
| NCT05931367Obesity · United States, Australia, Canada and more | 3 | Completed | Eli Lilly | Nov 14, 2025 | 445 |
| NCT05929079Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more | 3 | Completed | Eli Lilly | Jun 16, 2026 | 1,152 |
| NCT05929066Obesity · United States, Australia, Brazil and more | 3 | Completed | Eli Lilly | Apr 6, 2026 | 2,335 |
| NCT05916560Hepatic Insufficiency · United States | 1 | Completed | Eli Lilly | Mar 2, 2025 | 43 |
| NCT05882045Obesity · United States, Argentina, Australia and more | 3 | Completed | Eli Lilly | Apr 16, 2026 | 1,946 |
| NCT05757531Healthy · United States | 1 | Completed | Eli Lilly | Jun 23, 2023 | 7 |
| NCT05611957Renal Insufficiency · United States | 1 | Completed | Eli Lilly | Sep 5, 2023 | 29 |
| NCT05548231Overweight · China | 1 | Completed | Eli Lilly | Jul 27, 2023 | 32 |
| NCT05445232Obesity · United States | 1 | Completed | Eli Lilly | Feb 24, 2023 | 32 |
| NCT04881760Obesity · United States, Puerto Rico | 2 | Completed | Eli Lilly | May 16, 2022 | 338 |
| NCT04867785Diabetes Mellitus, Type 2 · United States, Puerto Rico | 2 | Completed | Eli Lilly | Jul 8, 2022 | 281 |
| NCT04823208Diabetes Mellitus, Type 2 · Japan | 1 | Completed | Eli Lilly | Jun 23, 2022 | 64 |
| NCT04143802Diabetes Mellitus, Type 2 · United States | 1 | Completed | Eli Lilly | Dec 28, 2020 | 72 |
| NCT03841630Healthy · Singapore | 1 | Completed | Eli Lilly | Jul 25, 2019 | 45 |
How it is read
Names in the registry
- “Retatrutide”, 18 entries
- “LY3437943”, 14 entries
- “Retatrutide (LY3437943)”, 1 entry
- “[¹⁴C]-LY3437943”, 1 entry
Conditions, from the studies’ own filings
- Obesity, 14 studies
- Diabetes Mellitus, Type 2, 8 studies
- Atherosclerosis, 1 study
- Non-alcoholic Fatty Liver Disease, 1 study
- Diabetes Mellitus, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.